{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = S-[(7''R'',8''R'',9''S'',10''R'',13''S'',14''S'',17''R'')-10,13-dimethyl-3-oxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
| image = Spiroxasone.png
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 6673-97-8
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 23141
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 21652
| UNII = 8P0U2ZA1NQ
| KEGG = D05912
| ChEBI = 
| ChEMBL = 2105514

<!--Chemical data-->
| C=24 | H=34 | O=3 | S=1
| molecular_weight = 402.593 g/mol
| SMILES = CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCCO5)C
| StdInChI_Ref = 
| StdInChI = 1S/C24H34O3S/c1-15(25)28-20-14-16-13-17(26)5-9-22(16,2)18-6-10-23(3)19(21(18)20)7-11-24(23)8-4-12-27-24/h13,18-21H,4-12,14H2,1-3H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1
| StdInChIKey_Ref = 
| StdInChIKey = XKCGICBTWRNUCL-KIEAKMPYSA-N
| synonyms = 
}}

'''Spiroxasone''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) is a [[synthetic compound|synthetic]], [[steroid]]al [[antimineralocorticoid]] of the [[spirolactone]] group which was developed as a [[diuretic]] and [[antihypertensive agent]] but was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1114|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=1114–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA261|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=261–}}</ref> It was [[chemical synthesis|synthesized]] and [[bioassay|assayed]] in 1963.<ref name="Elks2014" /> The drug is 7α-acetylthiospirolactone with the [[ketone]] [[functional group|group]] removed from the C17α spirolactone [[ring (chemistry)|ring]].<ref name="Elks2014" /> Similarly to other spirolactones like [[spironolactone]], spiroxasone also possesses [[antiandrogen]] activity.<ref name=""Elsevier1979">{{cite book|title=Progress in Medicinal Chemistry|url=https://books.google.com/books?id=wesIAirSEDkC&pg=PA69|date=1 January 1979|publisher=Elsevier|isbn=978-0-08-086264-4|pages=69–|quote=Spiroxasone [...] is also an anti-androgen [379].}}</ref><ref name="pmid4654667">{{cite journal | vauthors = Rasmusson GH, Chen A, Reynolds GF, Patanelli DJ, Patchett AA, Arth GE | title = Antiandrogens. 2',3' -Tetrahydrofuran-2'spiro-17-(1,2 -methylene-4-androsten-3-ones) | journal = J. Med. Chem. | volume = 15 | issue = 11 | pages = 1165–8 | year = 1972 | pmid = 4654667 | doi = | url = }}</ref>

==References==
{{Reflist|2}}


{{Androgen receptor modulators}}
{{Mineralocorticoid receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:Acetate esters]]
[[Category:Antiandrogens]]
[[Category:Antimineralocorticoids]]
[[Category:Furans]]
[[Category:Pregnanes]]
[[Category:Spiro compounds]]
[[Category:Thioesters]]


{{steroid-stub}}
{{cardiovascular-drug-stub}}